BioCryst Pharmaceuticals ... (BCRX)
NASDAQ: BCRX
· Real-Time Price · USD
7.60
-0.05 (-0.65%)
At close: Sep 26, 2025, 11:05 AM
-0.65% (1D)
| Bid | 6.58 |
| Market Cap | 1.6B |
| Revenue (ttm) | 557.51M |
| Net Income (ttm) | -35.71M |
| EPS (ttm) | -0.18 |
| PE Ratio (ttm) | -42.21 |
| Forward PE | 14.39 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 8.69 |
| Volume | 318,428 |
| Avg. Volume (20D) | 3,051,965 |
| Open | 7.71 |
| Previous Close | 7.65 |
| Day's Range | 7.57 - 7.73 |
| 52-Week Range | 6.02 - 11.31 |
| Beta | 1.13 |
| Ex-Dividend Date | n/a |
About BCRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsBioCryst Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+9.81%
BioCryst Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
4 months ago
+23.52%
BioCryst Pharmaceuticals shares are trading higher after the company reported a Q1 sales beat.
1 month ago · seekingalpha.com
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call TranscriptBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Babar Ghias - CFO & Head of Corporate Development Charles K. Gayer - Presi...
1 month ago · fool.com
BioCryst (BCRX) Q2 Revenue Jumps 50%BioCryst (BCRX) Q2 Revenue Jumps 50%
